Drug loading in nanoparticles, with their application in nanomedicine, finds potential benefits over free drugs with increased drug bioavailability, reduced side effects, improved targeted delivery, and controlled drug release. However, the current nanomaterial systems, including metallic, polymer, protein, lipids, and other nanoparticles, face severe challenges with poor drug loading efficiency. This limitation can affect the amount of drug that can be incorporated, potentially requiring higher doses or alternative strategies for certain medications. Several studies have been carried out to improve drug loading efficiency in nanomaterials. However, the process is labor-intensive, expensive, time-consuming, unscalable, and needs subject expertise, and the surface engineering process differs from material to material. Therefore, there is a need for the development of a common platform to enhance drug-loading efficiency for all the nanomaterials. In our research work, we have explored the potential of microgravity as a novel platform for enhancing drug-loading efficiency in nanomaterials. The drug loading efficiency was found to be increased more than two-fold in iron oxide nanoparticles (from 50.4 ± 2.3 % to 99 ± 0.05 % with sustained drug release for 120 h) and four-fold in liposomes (from 14.28 ± 0.4 % to 97.2 ± 1 % with sustained drug release for 12 h). We also confirmed that the microgravity-based drug-loaded nanomaterials exhibited excellent drug release, biocompatibility, and anticancer efficacies against breast cancer (MCF-7) cells. Our findings set the stage for exploring microgravity as a unique platform to enhance drug loading efficiency in nanomaterials, paving the way for innovative developments in drug delivery and space-based pharmaceutical research.
Read full abstract